Biocon Limited has informed the Exchange about Notification to Stock Exchange
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's wholly owned subsidiary, Biocon Pharma Limited, has received US FDA approval for its ANDA (generic version) of Rivaroxaban Tablets in four strengths: 2.5 mg, 10 mg, 15 mg, and 20 mg. Rivaroxaban is a widely used blood-thinning medication prescribed for treating deep vein thrombosis, pulmonary embolism, and reducing stroke risk in patients with nonvalvular atrial fibrillation. The company stated this approval will further strengthen its portfolio of vertically integrated drug products. No revenue guidance or specific commercial launch timeline was provided in the filing.
Positive for Biocon — this opens the door to commercialising a generic version of a blockbuster drug (brand name Xarelto) in the large US market, potentially adding to future revenues and reinforcing the company's generic formulations pipeline.